In the final days of 2023, an adult with hemophilia A named Maxwell became the first person in the U.S. to receive treatment with the one-time gene therapy Roctavian (valoctocogene roxaparvovec-rvox) — approved in June of last year — outside of clinical trials. “Receiving this treatment is liberating…
Albumin fusion is a molecular technology that has been used to create replacement therapies for hemophilia with an extended half-life — treatments that are more long-lasting in the body and can therefore be administered less frequently.
Although hemophilia, a bleeding disorder that interferes with blood clotting, is more common in men, women can have it, too.
Hemophilia News Today brought you coverage of the latest developments in research and advances in treatments for hemophilia in 2023. Here we’ve compiled a list of the top 10 most-read articles published on our site last year. We hope to continue being a resource for the hemophilia community…
Healthcare costs are comparable for male patients with hemophilia A who are treated with either Adynovate (rurioctocog alfa pegol) or Eloctate (efmoroctocog alfa), according to a real-world study in the U.S. “Results from this analysis may be used to inform product coverage and treatment decisions valuable for both…
The parents of most children with severe hemophilia A who took part in the XTEND-Kids clinical trial of Altuviiio (efanesoctocog alfa) reported in exit interviews that the once-weekly treatment led to notable improvements in mood for their sons, with some reporting a greater ability for their boys to…
The once-weekly injection therapy marstacimab is being considered for approval in both the U.S. and Europe for people with hemophilia A and hemophilia B who don’t have inhibitors. The U.S. Food and Drug Administration (FDA) is expected to decide on it in late 2024, while a decision from the European…
Eloctate (efmoroctocog alfa) is an extended half-life therapy that's approved to prevent and treat bleeds, including those occurring during surgery, in adults and children with hemophilia A.
Last updated Nov. 21, 2023, by Margarida Maia, PhD ✅ Fact-checked by Joana Carvalho, PhD What is Obizur for hemophilia? Obizur (susoctocog alfa) is a recombinant, or man-made, antihemophilic factor therapy approved for the on-demand treatment of bleeding episodes in adults with acquired…
Rebinyn (nonacog beta pegol, or N9-GP) is an extended half-life product approved for treating and preventing bleeds, including those occurring during surgery, in adults and children with hemophilia B.
Get regular updates to your inbox.
